Novartis Returns OUS Rights for Jetrea to ThromboGenics

September 22, 2017: By Jon Swedien

April 2014 OMP ThromboGenics’ JetreaThromboGenics regained full global rights to Jetrea after reaching an agreement with Novartis, whose subsidiary, Alcon, had held the rights outside the US (OUS), ThromboGenics announced Sept. 18.

Jetrea (ocriplasmin), launched in January 2013, is a one-time, single intravitreal injection to treat adults with symptomatic vitreomacular adhesion.

In 2012, ThromboGenics struck an agreement with Novartis to license Jetrea’s OUS rights to Alcon.

Under that agreement, ThromboGenics received an upfront payment of €75 million ($97.9 million, conversion March 16, 2012) and was eligible to receive up to €300 million ($391.5 million, conversion March 16, 2012) more in potential milestone payments.

Under the new agreement, Novartis will pay ThromboGenics €53.7 million ($64.1 million, conversion Sept. 18, 2017) in cash and make a forthcoming equity investment of €10 million ($11.1 million, conversion Sept. 18, 2017) in ThromboGenics capital, ThromboGenics said.

Following the agreement, ThromboGenics will have more than €120 million in cash, the Belgium firm said.

The agreement stipulates Alcon and Novartis will work closely with ThromboGenics to ensure continuity and access to Jetrea for existing and future customers, ThromboGenics said.

In March 2017, ThromboGenics announced it would take an impairment charge of €26.6 million to align its Jetrea goodwill value with continued lower-than-expected sales.

Novartis took an impairment charge of $119 million on Jetrea in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023